International Clinical Trial: A non-inferiority, randomized, controlled, multicenter, phase II clinical study was conducted to evaluate the efficacy and safety of triaciclib in the first-line treatment of advanced squamous non-small cell lung cancer with paclitaxel or albumin-paclitaxel combined with carboplatin and tislelizumab

Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500115243) titled 'A non-inferiority, randomized, controlled, multicenter, phase II clinical study was conducted to evaluate the efficacy and safety of triaciclib in the first-line treatment of advanced squamous non-small cell lung cancer with paclitaxel or albumin-paclitaxel combined with carboplatin and tislelizumab' on Dec. 24, 2025.

Study Type: Interventional study

Study Design: Parallel

Primary Sponsor: Dongguan People's Hospital

Condition: Advanced squamous non-small cell lung cancer

Intervention: Experimental group:Albumin paclitaxel or paclitaxel + carboplatin + tislelizumab + trilaciclib

Recruitment Status: Not Rec...